RPL7P9

Across TCGA pan-cancer cohorts, RPL7P9 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPL7P9 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RPL7P9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RPL7P9 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC and CCRCC are the cancer types where RPL7P9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	II,III,IV	1.000	0.530	.024	3	view →
CCRCC	OS	Quartile	All	0.674	0.966	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RPL7P9–LSCC (OS)

Open the LSCC breakdown →